The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000732381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
9/04/2026
Date registered
Help: Date registered
17/06/2026
Date last updated
Help: Date last updated
29/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
ECHIDNA Study - Exploring Children's Healthcare Improvement; Delivery of subcutaNeous Antibiotics: Assessing subcutaneous compared with intravenous ceftriaxone, cefazolin, and meropenem in hospitalised children.
Scientific title
A prospective, open-label, two-period crossover Phase 2a trial to determine absolute bioavailability, pharmacokinetics, safety, and acceptability of subcutaneous compared with intravenous ceftriaxone, cefazolin, and meropenem in hospitalised children.
Additional trial identifiers [1] 316597 0
Nil
Universal Trial Number (UTN)
Trial acronym
ECHIDNA
Related trial records

Health condition
Health condition(s) studied:
Paediatric infections 340784 0
Condition category
Condition code
Infection 336958 336958 0 0
Studies of infection and infectious agents
Public Health 337690 337690 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention: Subcutaneous (SC) administration of clinically indicated ceftriaxone, cefazolin, or meropenem, diluted in normal saline, administered via an indwelling subcutaneous catheter device.

A subcutaneous cannula will be inserted at an appropriate site (e.g. abdomen or thigh). Pre-procedural comfort measures as part of standard care, include the use of oral sucrose for infants and topical anaesthetic (e.g. EMLA cream in children older than 3 months of age), will be offered to each participant prior to the procedures. An IV device may be left in situ whilst the SC treatment-route is completed to allow return to IV therapy and minimise procedures.

Dose administered: max 2g / dose for each antibiotic

Frequency: Ceftriaxone – 12 or 24-hourly. Cefazolin – 6 or 8 hourly. Meropenem – 8 hourly. Duration: 20 mL over 30 mins, followed by a 5 mL saline flush.

Total duration: up to 48 hours

Who will administer: Ward nursing staff

Strategies to assess adherence to intervention: Participant compliance, including route and timing adherence, will be assessed using prescription medication records and source documentation, including infusion start and finish times. An acceptability rating survey for the parent/caregiver, child/adolescent and healthcare worker will also be performed. If the allocated route of administration cannot be continued (e.g. intolerance, device failure, adverse event, clinical deterioration), participants may switch early to the alternate route or routine care. Early treatment route switches are recorded with the reason documented.

No pharmacological washout is required, given beta-lactams have short half-lives, comparison is within-subject and PK modelling accounts for time and dosing history. The alternate antibiotic administration route will be used for the next dose.

Ceftriaxone, Cefazolin and Meropenem will be assessed and analysed separately. Participants will only receive one of the three antibiotics.
Intervention code [1] 333730 0
Treatment: Devices
Intervention code [2] 334105 0
Treatment: Drugs
Description of the comparator or control
Comparator: Intravenous (IV) administration of the same antibiotic, dose, and frequency according to standard clinical practice.

A new IV catheter is required, only if IV access is not already established as part of routine care in accordance with hospital guidelines. Pre-procedural comfort measures as part of standard care, include the use of oral sucrose for infants and topical anaesthetic (e.g. EMLA cream in children older than 3 months of age), will be offered to each participant prior to the procedures. An IV device may be left in situ whilst the SC treatment-route is completed to allow return to IV therapy and minimise procedures.

Dose administered: max 2g / dose for each antibiotic

Frequency & Duration: Ceftriaxone – 12 or 24-hourly, infused over 30 mins. Cefazolin – 6 or 8 hourly, infused over 10-60 mins. Meropenem – 8 hourly, infused over 15-30 mins.

Total duration: up to 48 hours

Who will administer: Ward nursing staff

Strategies to assess adherence to intervention: Participant compliance, including route and timing adherence, will be assessed using prescription medication records and source documentation, including infusion start and finish times. An acceptability rating survey for the parent/caregiver, child/adolescent and healthcare worker will also be performed. If the allocated route of administration cannot be continued (e.g. intolerance, device failure, adverse event, clinical deterioration), participants may switch early to the alternate route or routine care. Early treatment route switches are recorded with the reason documented.
Control group
Active

Outcomes
Primary outcome [1] 345023 0
Absolute bioavailability of subcutaneous compared with intravenous administration, measured by the ratio of area under the concentration-time curve
Timepoint [1] 345023 0
During each treatment period, based on pharmacokinetic sampling over the dosing interval. Ceftriaxone 12-hourly: SC treatment period – 1hr, 3hr, 8hr, 12hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 12hr post-end of infusion (pre-next dose). Ceftriaxone 24-hourly: SC treatment period – 1hr, 3hr, 8hr, 24hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 24hr post-end of infusion (pre-next dose). Cefazolin 6-hourly: SC treatment period – 1hr, 2hr, 4hr, 6hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 6hr post-end of infusion (pre-next dose). Cefazolin 8-hourly: SC treatment period – 1hr, 2hr, 4hr, 8hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 8hr post-end of infusion (pre-next dose). Meropenem: SC treatment period – 1hr, 2hr, 5hr, 8hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 8hr post-end of infusion (pre-next dose).
Secondary outcome [1] 460172 0
Population pharmacokinetic parameters, including clearance and volume of distribution
Timepoint [1] 460172 0
During each treatment period, based on pharmacokinetic sampling over the dosing interval. Ceftriaxone 12-hourly: SC treatment period – 1hr, 3hr, 8hr, 12hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 12hr post-end of infusion (pre-next dose). Ceftriaxone 24-hourly: SC treatment period – 1hr, 3hr, 8hr, 24hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 24hr post-end of infusion (pre-next dose). Cefazolin 6-hourly: SC treatment period – 1hr, 2hr, 4hr, 6hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 6hr post-end of infusion (pre-next dose). Cefazolin 8-hourly: SC treatment period – 1hr, 2hr, 4hr, 8hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 8hr post-end of infusion (pre-next dose). Meropenem: SC treatment period – 1hr, 2hr, 5hr, 8hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 8hr post-end of infusion (pre-next dose).
Secondary outcome [2] 460173 0
Pharmacodynamic target attainment, including percentage of time above minimum inhibitory concentration
Timepoint [2] 460173 0
During each treatment period, based on pharmacokinetic sampling over the dosing interval. Ceftriaxone 12-hourly: SC treatment period – 1hr, 3hr, 8hr, 12hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 12hr post-end of infusion (pre-next dose). Ceftriaxone 24-hourly: SC treatment period – 1hr, 3hr, 8hr, 24hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 24hr post-end of infusion (pre-next dose). Cefazolin 6-hourly: SC treatment period – 1hr, 2hr, 4hr, 6hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 6hr post-end of infusion (pre-next dose). Cefazolin 8-hourly: SC treatment period – 1hr, 2hr, 4hr, 8hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 8hr post-end of infusion (pre-next dose). Meropenem: SC treatment period – 1hr, 2hr, 5hr, 8hr post-end of infusion (pre-next dose). IV treatment period – 0.5-1hr, 8hr post-end of infusion (pre-next dose).
Secondary outcome [3] 460174 0
Safety outcomes, including adverse events such as local site reactions and catheter-related complications
Timepoint [3] 460174 0
Adverse event details will be collected immediately after device insertion, mid-infusion, end of infusion, 30 min post-infusion, at the end of each treatment-route period, and 48 hours after the last dose. Additional assessments will be performed if triggered by symptoms/clinical concern.
Secondary outcome [4] 460175 0
Pain assessed using validated paediatric pain scales
Timepoint [4] 460175 0
Pain assessments will occur immediately after device insertion and mid-infusion, end of infusion and 30 minutes post-dose infusion for both SC and IV treatment methods.
Secondary outcome [5] 460178 0
Acceptability of administration route as reported by participants, caregivers and clinicians using Likert-scale questionnaires
Timepoint [5] 460178 0
At completion of each treatment period
Secondary outcome [6] 460179 0
Clinical outcomes at 30 days including hospital readmission.
Timepoint [6] 460179 0
During hospital admission and follow-up to 30 days
Secondary outcome [7] 461726 0
Clinical outcomes at 30 days including microbiological treatment failure
Timepoint [7] 461726 0
During hospital admission and follow-up to 30 days
Secondary outcome [8] 461727 0
Clinical outcomes at 30 days including all-cause mortality.
Timepoint [8] 461727 0
During hospital admission and follow-up to 30 days

Eligibility
Key inclusion criteria
1. Aged below 18 years and weight of at least 3.5 kg.

2. Admitted to the hospital study site.

3. Prescribed ceftriaxone, cefazolin or meropenem as part of routine care, planned for more than 24 hours.
Minimum age
0 Days
Maximum age
6570 Days
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Requirement for intensive care admission or medical emergency team (MET) call within the previous 24 hours.
2. Known severe hypersensitivity to ß-lactam antibiotics (e.g.anaphylaxis, severe cutaneous reaction).
3. Severe skin disease at proposed SC administration sites that would preclude safe infusion.
4. The primary treating clinician deems enrolment not in the best interests of the child.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Stratification by antibiotic cohort
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Pharmacokinetics
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29374 0
Perth Children's Hospital - Nedlands
Recruitment postcode(s) [1] 45692 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 321215 0
Charities/Societies/Foundations
Name [1] 321215 0
Telethon Trust
Country [1] 321215 0
Australia
Primary sponsor type
Government body
Name
Child and Adolescent Health Service (Perth Children's Hospital)
Address
Country
Australia
Secondary sponsor category [1] 323923 0
Other
Name [1] 323923 0
Wesfarmers Centre of Vaccines and Infectious Diseases
Address [1] 323923 0
Country [1] 323923 0
Australia
Secondary sponsor category [2] 324383 0
Other
Name [2] 324383 0
The Kids Research Institute Australia
Address [2] 324383 0
Country [2] 324383 0
Australia
Secondary sponsor category [3] 324384 0
University
Name [3] 324384 0
The University of Western Australia
Address [3] 324384 0
Country [3] 324384 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319741 0
Child and Adolescent Health Service Human Research Ethics Committee
Ethics committee address [1] 319741 0
Ethics committee country [1] 319741 0
Australia
Date submitted for ethics approval [1] 319741 0
20/02/2026
Approval date [1] 319741 0
13/04/2026
Ethics approval number [1] 319741 0
RGS0000008275

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148254 0
Dr Anita Campbell
Address 148254 0
Perth Children's Hospital, 15 Hospital Avenue, Nedlands WA 6009
Country 148254 0
Australia
Phone 148254 0
+61 08 6456 2222
Fax 148254 0
Email 148254 0
Contact person for public queries
Name 148255 0
Chloe Cheng
Address 148255 0
Perth Children's Hospital, 15 Hospital Avenue, Nedlands WA 6009
Country 148255 0
Australia
Phone 148255 0
+61 08 6456 2222
Fax 148255 0
Email 148255 0
Contact person for scientific queries
Name 148256 0
Anita Campbell
Address 148256 0
Perth Children's Hospital, 15 Hospital Avenue, Nedlands WA 6009
Country 148256 0
Australia
Phone 148256 0
+61 08 6456 2222
Fax 148256 0
Email 148256 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.